Objective:Human genetic resources are valuable biological resources with significant importance in medical research, population genetics, and other fields. This paper focuses on ″human genetic resources data management″, analyzing the management practices at National Medical Center Fudan University Zhongshan Hospital, and proposing optimization strategies for current management issued to enhance data security protection and compliance.Methods:Based on case analysis methodology, this study systematically reviewed the hospital′s human genetic resources data management practices. Through statistical correlation analysis, the relationship between resource application quantities and applicants′ research outputs was validated.Results:The findings revealed that basic research dominates human genetic resources applications, primarily focusing on genetic testing, drug trials, and neoadjuvant therapies. Correlation analysis demonstrated a significant positive correlation between the number of human genetic resources applications and applicants′ research outputs, indicating that utilization of human genetic resources was closely related to research productivity.Conclusions:Based on the main issues identified at the hospital management level, optimization measures such as refining management scope, technological innovation empowerment, data standardization, and data interoperability are beneficial for enhancing data security protection and compliance. It is necessary to establish relevant training systems and implementation standards to ensure the safe and effective management of human genetic resources data.

Objective:Human genetic resources are valuable biological resources with significant importance in medical research, population genetics, and other fields. This paper focuses on ″human genetic resources data management″, analyzing the management practices at National Medical Center Fudan University Zhongshan Hospital, and proposing optimization strategies for current management issued to enhance data security protection and compliance.Methods:Based on case analysis methodology, this study systematically reviewed the hospital′s human genetic resources data management practices. Through statistical correlation analysis, the relationship between resource application quantities and applicants′ research outputs was validated.Results:The findings revealed that basic research dominates human genetic resources applications, primarily focusing on genetic testing, drug trials, and neoadjuvant therapies. Correlation analysis demonstrated a significant positive correlation between the number of human genetic resources applications and applicants′ research outputs, indicating that utilization of human genetic resources was closely related to research productivity.Conclusions:Based on the main issues identified at the hospital management level, optimization measures such as refining management scope, technological innovation empowerment, data standardization, and data interoperability are beneficial for enhancing data security protection and compliance. It is necessary to establish relevant training systems and implementation standards to ensure the safe and effective management of human genetic resources data.

OBJECTIVE To discuss medical insurance access and pricing methods for multi-indication drugs. METHODS The access situation of multi-indication drugs in China’s medical insurance negotiation over the years was sorted out. Referring to the economic theory of value-based pricing and the relevant experience of other countries， five applicable pricing methods of 3 categories for multi-indication drug in China were summarized. Taking ceftazidime-avibactam（CAZ-AVI） as an example， cost- utility analyses were performed for different indications， and appropriate pricing methods were applied. RESULTS & CONCLUSIONS All multi-indication drugs in China adopted a single pricing method. The pricing methods that could be explored include product-based pricing， such as single pricing based on the lower-value indication or mixed/weighted single pricing； indication-based pricing， such as developing a new agreement for single pricing under different discounts and listing with different brands and pricing of the same medicine for different indications； and compensation for access restrictions. Each method has its advantages and limitations. The case of CAZ-AVI showed that it is necessary to estimate the value of each indication for multi- indication drugs， and comprehensively consider appropriate access conditions and pricing methods based on value. Although single pricing is simple to operate， it is different to reflect the value entirely. The indication-based pricing and compensation for access restrictions all depend on the information collection system and the cooperation of multiple departments. China is supposed to carry out the value-based pricing of multi-indication drugs and constantly explore reasonable access methods to improve overall social welfare.

Objective To construct and validate a predictive model for the risk of bone metastasis in patients with primary liver cancer. Methods The research was generally divided into two parts: model establishment and model validation. A total of 197 patients with primary liver cancer from January 2018 to June 2018 were selected to be included in the study when building the model, and the nomogram prediction model based on Cox regression was used in the case-control study method. The validation process continued to select 238 patients with primary liver cancer (no bone metastasis) in our hospital (from July 2018 to December 2018) and followed up for 3 years. The information of the prognosis of bone metastasis during the follow-up period was observed and collected to complete the validation. SPSS statistical software and R software were used to complete the data analysis. Results The results of regression analysis at the stage of building the model showed that age, family history of malignant tumor, previous history of hepatitis B, tumor stage, primary focus surgery and tumor differentiation were independent factors affecting the prognosis of patients with bone metastasis (P <0.05). The nomogram clinical prediction model was established by using R software. The prediction model finally included four factors: age, previous history of hepatitis B, primary surgery, and degree of differentiation. The AUC of ROC curve for predicting the risk of bone metastasis was 0.758. Conclusion The nomogram model constructed in this study has a medium to high degree of predictive calibration for predicting the risk of bone metastasis in patients with primary liver cancer within 3 years and is worthy of clinical auxiliary use.

Objective: To provide reliable prediction models based on dentoskeletal and soft tissue variables for customizing maxillary incisor positions and to optimize digitalized orthodontic treatment planning. Methods: This study included 244 Chinese women (age, 18–40 years old) with esthetic profiles after orthodontic treatment with fixed appliances (133 in group I: 1° ≤ The angle between the nasion [N]-A point [A] plane and the N-B point [B] plane [ANB] ≤ 4°; 111 in group II: 4° < ANB ≤ 7°). Dental, skeletal, and soft tissue measurements were performed on lateral cephalograms of the participants. Correlation and multiple linear regression analyses were used to determine the influence of dentoskeletal and soft tissue variables on maxillary incisor position. Results: The ideal anteroposterior position of the maxillary incisor varied between sagittal skeletal patterns. The position of the maxillary incisor correlated with the sagittal discrepancy between the maxilla and the mandible (ANB), protrusion of the midface, nasal tip projection, development of the chin, and inclination of both the maxillary and mandibular incisors. Distance from the maxillary central incisor to nasion-pogonion plane predicted using multiple linear regression analysis was accurate and could be a practical measurement in orthodontic treatment planning. Conclusions Instead of using an average value or norm, orthodontists should customize a patient’s ideal maxillary incisor position using dentoskeletal and soft tissue evaluations.

Objective: To investigate the health of gypsum miners in Hubei province and analyze the health effects of occupational disease hazards exposure on gypsum miners. Methods: In April 2017, occupational disease hazard factors were tested on the site of a gypsum mine, and 500 workers were selected by random sampling to conduct questionnaires, relevant data such as occupational health examination was collected, and descriptive statistical analysis was performed. Results: The main occupational hazards of gypsum miners were gypsum dust and noise. The time-weighted average concentration of 8 h in the workplace was 4.32 to 9.34 mg/m³, and the post pass rate was 69.2% (9/13) ; Respiratory dust 0.13-5.15 mg/m³, post pass rate 75.0% (3/4). Gypsum miners had finger dysfunction and muscle numbness, joint pain (29.2%, 88/301) and chest pain and breathing difficulties (17.6%, 53/301). Followed by tinnitus, auricle pus, running water (4.7%, 14/301), abnormal muscle tension (2.7%, 8/301). The exposure of occupational disease hazards was associated with respiratory, auditory and neurological symptoms of gypsum miners. Conclusion The long-term exposure of gypsum workers to gypsum dust, noise and other harmful factors may result in obvious symptoms of respiratory system and other health damage.

PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population. MATERIALS AND METHODS: Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP-14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities. RESULTS: Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ≥ 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21. CONCLUSION: R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ≥ 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.
Asian Continental Ancestry Group ; B-Lymphocytes ; Cyclophosphamide ; Disease-Free Survival ; Doxorubicin ; Follow-Up Studies ; Humans ; Lymphoma, B-Cell ; Prednisone ; Prognosis ; Rituximab ; Vincristine

OBJECTIVETo investigate the association between the polymorphisms of [c.-2922(C)2-3 and IVS6+ 18insG] in the NURR1 gene and Parkinson's disease (PD) in a Han population from Sichuan province.

METHODSPCR, allele-specific PCR (AS-PCR) and restriction fragment length polymorphism (RFLP) were used to determine the genotype of each subject.

RESULTSThe two polymorphic sites in 241 PD patients and 236 controls with matched age, gender and ethnicity were analyzed. In the IVS6+ 18insG site, the difference of genotype frequencies of 3G/3G, 3G/2G and 2G/2G was not statistically significant. However, the 3G/2G genotype frequency was significantly higher in the PD with age of onset being < 50 years than that in controls (chi (2)= 6.537, P= 0.011; OR= 1.913, 95%CI: 1.159-3.158). No significant differences were found in allele and genotype frequencies of the c.-2922(C)2-3 site in the promoter region between the PD and controls (P= 0.766).

CONCLUSIONThis study suggested that the IVS6+ 18insG polymorphism may be associated with genetic susceptibility of PD with age of onset being < 50 years and the c.-2922(C)2-3 site in the promoter region may not be a risk factor for PD in authors' patient group.

Adult ; Age of Onset ; Aged ; Aged, 80 and over ; Asian Continental Ancestry Group ; genetics ; Base Sequence ; Case-Control Studies ; DNA-Binding Proteins ; genetics ; Ethnic Groups ; genetics ; Female ; Gene Frequency ; Genotype ; Humans ; Male ; Middle Aged ; Nuclear Receptor Subfamily 4, Group A, Member 2 ; Parkinson Disease ; genetics ; pathology ; Polymorphism, Genetic ; Sex Factors ; Transcription Factors ; genetics